Endocrinological and Pathological Effects of Anabolic-Androgenic Steroid in Male Rats

Total Page:16

File Type:pdf, Size:1020Kb

Endocrinological and Pathological Effects of Anabolic-Androgenic Steroid in Male Rats Endocrine Journal 2004, 51 (4), 425–434 Endocrinological and Pathological Effects of Anabolic-androgenic Steroid in Male Rats MASATO TAKAHASHI, YUKITOSHI TATSUGI AND TOSHIHIKO KOHNO International Budo University Faculty of Physical Education, Chiba 299-5295, Japan Abstract. Many athletes use drugs, especially anabolic androgenic steroids (AAS), but there are few reports on the endocrinological and pathological changes in AAS abusers. In this study we reported the results of endocrinological examinations in rats administered AAS and also physical changes. We separated 37 male Wistar rats (7 weeks old) into 3 groups: Group A was medicated with nandrolone decanoate, metenolone acetate, and dromostanolone; Group B with nandrolone decanoate and saline; and Group C was given only saline. They were given subcutaneous injections of the medications or the control vehicle once a week for 6 weeks. Medications were stopped for 4 weeks, and then resumed for another 6 weeks. After that, rats were sacrificed. Serum testosterone level in Group A was significantly higher than that in Group C. Serum dihydrotestosterone in Group A was significantly higher than that in both Groups B and C. Serum estradiol-17 levels in Groups A and B were significantly higher than that in Group C. In pathological evaluation, heart, testis, and adrenal gland were severely damaged. These findings indicate that there is a high degree of risk related to the use of AAS. Key words: Anabolic androgenic steroid, Doping in sports, Endocrinology, Pathology (Endocrine Journal 51: 425–434, 2004) BEN Johnson, a Canadian athlete who used the control efforts has naturally been fewer than those in anabolic-androgenic steroid (AAS) stanozolol, was other countries [3, 4]. Because AAS abuse in athletics disqualified from the Seoul Olympics in an effort to is widespread the side effects elicited by AAS abuse control doping. After this notorious incident, reports have been extensively reported [5–10]. of such cases have been numerous. In Japan, body- Psychotic states and infertility have social implica- builders and the other athletes sometimes test positive tions [11–15] and are among the serious side effects for AAS use. Takahashi, who has investigated AAS elicited by AAS abuse. However, the pathophysiology abuse among Japanese athletes, reported two cases of and prognosis of AAS use remains unclear. Bashin et doping by Japanese athlete [1, 2]. Traditionally, it has al., Berman et al., Bross et al., and Tricker et al. been thought that Japanese athletes refrain from AAS attempted to quantify the side effects of testosterone use and so the public was shocked to hear of these in- administration in humans [16–19]. As is unethical to cidents. Greater anti-doping efforts and treatment for administer high doses of AAS in humans, in the the deleterious side effects of these drugs in Japanese current study we have used animals to determine the athletes are needed. However, since doping control in pathology and prognosis resulting from AAS use. We Japan has been minimal in the past, the number of previously reported the results of hematological and Japanese doctors and scientists participating in doping biochemical examinations following AAS administra- tion in rats, and included data reporting the changes in body and organ weights in these animals [20]. Based Received: April 2, 2003 Accepted: April 21, 2004 on our previous findings, we hypothesized that AAS Correspondence to: Dr. Masato TAKAHASHI, International Budo administration would result in significant deleterious University Faculty of Physical Education, 841, Shinkan, effects on organ tissue pathology and endocrine func- Katsuura, Chiba 299-5295, Japan tion. Pathological evaluation especially revealed 426 TAKAHASHI et al. severe damage to heart, testis, and adrenal gland. AAS nighttime hours. administration further resulted in a severe imbalance in the endocrine system. Endocrinological examinations Endocrinological examinations included measure- Methods ment of adrenocorticotropic hormone (ACTH) and atrial natriuretic peptide (ANP) in plasma, and corti- Animals and experimental conditions costerone, testosterone, dihydrotestosterone (DHT), estradiol-17 (E2), and erythropoietin (EPO) in serum. We separated 37 male Wistar rats (7 weeks old) Furthermore, we measured prostate specific antigen into 3 groups: Group A (n = 12) was administered (PSA). Organs were fixed in 10% neutral buffered nandrolone decanoate (8.33 × 10–2 mg/g; Sankyo Co. formalin. Next the heart, liver, kidney, spleen, adrenal Ltd., Tokyo), metenolone acetate (1.67 × 10–1 mg/g; gland, testis, prostate gland, and spleen were routinely Japan Schering Co., Ltd., Osaka), and dromostanolone processed for paraffin embedding. Organs were cut (8.33 × 10–2 mg/g; Shionogi Co., Ltd., Osaka); Group into 10 m thin sections and stained with hematoxylin B (n = 12) received nandrolone decanoate and saline; and eosin (H.E.). These tissue samples were then and Group C (n = 13) was given only saline. These examined under light microscope for quantification of drug dosages were converted from 100 times the gen- histopathological changes following AAS administra- eral dose for 60 kg body weight in humans, since this tion. dose has been previously found to be used by drug abusers [21]. Such doses were chosen based on the Statistical analysis fact that 100 times the normal dosing is necessary to pharmacologically investigate the pathological effects Significant differences were identified using one- of drug abuse. Each rat was housed in individual way ANOVA. If the ANOVA revealed significant cage (25 × 13 × 16 cm), and given access to rat chow main effects (p<0.05), Sheffe’s post-hoc method of one pellets (Oriental Yeast Co. Ltd., Tokyo) and water ad way factorial ANOVA and multiple comparison tests libitum. Temperature and moisture averaged 25 ± 2°C were then used. and 75 ± 10%, respectively. After a week of acclima- tion, animals were given subcutaneous injections of AAS or the control vehicle once a week for 6 weeks. Results Drug administration was stopped for 4 weeks, and then resumed for another 6 weeks. This dosing regimen Behavioral observations during experimental period was used to duplicate the “stacking” of AAS and the “steroid cycle” that is used by AAS abusers in athlet- After 3 weeks, some Group A and Group B rats ex- ics. These studies followed the ethical guidelines set hibited hair loss (Fig. 1). After 4 weeks, some Group by International Budo University. A (n = 5) and Group B rats (n = 9) exhibited such aggressive behavior that they could not be handled Sacrifice without gloves. After 5 weeks, some rats of Group B (n = 3) demonstrated extremely aggressive and hostile After two cycles of steroid administration, rats were behavior. After 1 cycle of AAS administration, all sacrificed by removing 12 ml of blood from the heart Group A and Group B animals exhibited inactive under ether anesthesia. Serum and plasma were pre- behavior, as evidenced by lack of locomotion upon served. We then extracted and recorded the wet stimulation. A very slow locomotor movement upon weight of skeletal muscles (M. extensor digitorum physical contact was further evident following this longus, M. gastrocnemius, M. plantaris, M. soleus, M. experiment. After 9 weeks, two rats of Group A and levator ani), liver, spleen, heart, kidney, adrenal gland, Group B caused self-inflicted injuries to their tails. and prostate gland. Collected blood and tissue sam- After 10 weeks, 6 of 12 rats in both Groups A and B ples were used to make a hormonal profile. In addi- were also observed to have self-inflicted bite wounds. tion, these experiments were performed during the After 2 cycles, all Group B and 4 rats of Group A EFFECTS OF ANABOLIC-ANDROGENIC STEROID 427 exhibited aggressive and hostile, behavior again. After 13 week, these rats became physically inactive (Fig. 2). Endocrinological profile The change the body weight is illustrated in Fig. 3 and a comparison of the organ weights is shown in Table 1. Results from endocrinological measurements are presented in Fig. 4. Data indicate that plasma ACTH in Groups A and B was significantly lower than in Group C (p<0.01). Changes in serum corticosterone exhibited no significant differences among the groups. Fig. 1. Rats experienced hair loss both systemically and at the Serum level of testosterone in Group A was signifi- site of subcutaneous AAS injections. Fig. 2. Experimental Behavioral observations during in Group A and Group B rats. This figure shows the change of physical activity. *Loss of hair, **Self inflicted tail wounds Fig. 3. Change of body weight in experimental period. Group A was administered 3 kinds of AAS. Group B was administered 1 kind of AAS and physiological saline. Control, Group C, was administered only physiological saline. 428 TAKAHASHI et al. Table 1. Body weight (BW), muscle weight and internal organ weight in rats which were treated by AAS in saline. Group A, treated which 3 kinds of AAS; Group B, treated with 1 kind of AAS, and Group C, treated with only saline. gastrocnemius gastrocnemius/ n BW (g) EDL (g) EDL/BW soleus (g) soleus/BW plantaris (g) plantaris/BW (g) BW A -group 12 506.5 ± 61.6 0.26 ± 0.04 0.51 ± 0.08 2.31 ± 0.31 4.57 ± 0.59 0.19 ± 0.05 0.37 ± 0.08 0.49 ± 0.06 0.98 ± 0.14 B -group 12 506 ± 17.3 0.26 ± 0.04 0.5 ± 0.07 2.45 ± 0.28 4.7 ± 0.53 0.18 ± 0.03 0.34 ± 0.07 0.53 ± 0.07 1.02 ± 0.15 C -group 13 642 ± 98.5 0.31 ± 0.04 0.48 ± 0.09 2.85 ± 0.23 4.47 ± 0.67 0.25 ± 0.06 0.39 ± 0.12 0.7 ± 0.2 1.08 ± 0.23 A-B A-B A-B
Recommended publications
  • Anabolic Steroid Use Misuse and Addiction
    Anabolic Steroid Use, Misuse And Addiction JASSIN M. JOURIA Dr. Jassin M. Jouria is a medical doctor, professor of academic medicine, and medical author. He graduated from Ross University School of Medicine and has completed his clinical clerkship training in various teaching hospitals throughout New York, including King’s County Hospital Center and Brookdale Medical Center, among others. Dr. Jouria has passed all USMLE medical board exams, and has served as a test prep tutor and instructor for Kaplan. He has developed several medical courses and curricula for a variety of educational institutions. Dr. Jouria has also served on multiple levels in the academic field including faculty member and Department Chair. Dr. Jouria continues to serve as a Subject Matter Expert for several continuing education organizations covering multiple basic medical sciences. He has also developed several continuing medical education courses covering various topics in clinical medicine. Recently, Dr. Jouria has been contracted by the University of Miami/Jackson Memorial Hospital’s Department of Surgery to develop an e-module training series for trauma patient management. Dr. Jouria is currently authoring an academic textbook on Human Anatomy & Physiology. ABSTRACT The synthetic versions of the male hormone testosterone, also known as anabolic steroids, can play an important role in the treatment of health conditions when used as prescribed by a medical clinician. However, misuse of anabolic steroids occurs when these substances are used solely to improve physical appearance or performance. Because there are some potentially serious physical effects of anabolic steroid use, it is important that anabolic steroids are only used as prescribed and always under a medical clinician’s guidance.
    [Show full text]
  • Effects of Androgenic-Anabolic Steroids on Apolipoproteins and Lipoprotein (A) F Hartgens, G Rietjens, H a Keizer, H Kuipers, B H R Wolffenbuttel
    253 Br J Sports Med: first published as 10.1136/bjsm.2003.000199 on 21 May 2004. Downloaded from ORIGINAL ARTICLE Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a) F Hartgens, G Rietjens, H A Keizer, H Kuipers, B H R Wolffenbuttel ............................................................................................................................... Br J Sports Med 2004;38:253–259. doi: 10.1136/bjsm.2003.000199 Objectives: To investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes. Methods: In a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2- C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined. Results: In study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l.
    [Show full text]
  • Metabolism of Anabolic Steroids in Man: Synthesis and Use of Reference Substances for Identification of Anabolic Steroid Metabolites
    Anaiytzca Chumca Acta, 275 (1993) 23-48 23 Elsevler hence Publishers B V , Amsterdam Metabolism of anabolic steroids in man: synthesis and use of reference substances for identification of anabolic steroid metabolites Will1 Schanxer and Manfred Domke LkutscheS’rthochschuk Koln, Inrhtut f?u Bwchemre, Carl-L&m-Weg 4 5ooO Cologne 41 (Germuny) (Recewed 20th May 1992) AhStl-& The use of anabohc steroids was banned by the International Olympic Comnuttee for the first tune at the Olympic Games m Montreal m 1976 Since that tie the nususe of anabohc steroxls by athletes has been controlled by analysis of urme extracts by gas chromatography-mass spectrometry @C-MS) The excreted steroids or their metabohtes, or both, are isolated from urme by XAD-2 adsorption, enzymatx hydrolyss of coqlugated excreted metabobtes anth /?-glucuromdase from Es&en&u co& bqmd-bqmd extractlon mth diethyl ether, and courted mto tnmethylsdyl (‘INiS) derwatwes The confirmation of an anabobc stenxd nususe ts based on comparison of the electron nnpact lomzation (EI) mass spectrum and GC retention tie of the isolated steroid and/or its metabohte with the El mass spectrum and GC retention time of authentic reference substances For this purpose excretion studies with the most common anabobc steroids were performed and the mam excreted metabobtes were synthesued for bolasterone, boldenone, 4-chiorodehydromethyltestosterone, clostebol, drostanolone, tluoxymesterone, forme- bolone, me&a&one, mesterolone, metandlenone, methandnol, metenolone, methyltestosterone, nandrolone, norethandrolone,
    [Show full text]
  • Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol Acetate Is Also Used in the Treatment of Ano- 16
    Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol acetate is also used in the treatment of ano- 16. Mwamburi DM, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar As for progestogens in general (see Progesterone, rexia and cachexia (see below) in patients with cancer results in 2 months. Clin Infect Dis 2004; 38: 895–902. p.2125). The weight gain that may occur with meges- or AIDS. The usual dose is 400 to 800 mg daily, as tab- 17. Grunfeld C, et al. Oxandrolone in the treatment of HIV-associ- ated weight loss in men: a randomized, double-blind, placebo- trol acetate appears to be associated with an increased lets or oral suspension. A suspension of megestrol ace- controlled study. J Acquir Immune Defic Syndr 2006; 41: appetite and food intake rather than with fluid reten- tate that has an increased bioavailability is also availa- 304–14. tion. Megestrol acetate may have glucocorticoid ef- ble (Megace ES; Par Pharmaceutical, USA) and is Hot flushes. Megestrol has been used to treat hot flushes in fects when given long term. given in a dose of 625 mg in 5 mL daily for anorexia, women with breast cancer (to avoid the potentially tumour-stim- cachexia, or unexplained significant weight loss in pa- ulating effects of an oestrogen—see Malignant Neoplasms, un- Effects on carbohydrate metabolism. Megestrol therapy der Precautions of HRT, p.2075), as well as in men with hot 1-3 4 tients with AIDS. has been associated with hyperglycaemia or diabetes mellitus flushes after orchidectomy or anti-androgen therapy for prostate in AIDS patients being treated for cachexia.
    [Show full text]
  • MMC International BV
    M.M.C. International Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Clenbuterol/ Oxymetholone Test Ephedrine Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on the Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange
    [Show full text]
  • Rapport 2008
    rapport 2008 Reseptregisteret 2004-2007 The Norwegian Prescription Database 2004-2007 Marit Rønning Christian Lie Berg Kari Furu Irene Litleskare Solveig Sakshaug Hanne Strøm Rapport 2008 Nasjonalt folkehelseinstitutt/ The Norwegian Institute of Public Health Tittel/Title: Reseptregisteret 2004-2007 The Norwegian Prescription Database 2004-2007 Redaktør/Editor: Marit Rønning Forfattere/Authors: Christian Lie Berg Kari Furu Irene Litleskare Marit Rønning Solveig Sakshaug Hanne Strøm Publisert av/Published by: Nasjonalt folkehelseinstitutt Postboks 4404 Nydalen NO-0403 Norway Tel: + 47 21 07 70 00 E-mail: [email protected] www.fhi.no Design: Per Kristian Svendsen Layout: Grete Søimer Acknowledgement: Julie D.W. Johansen (English version) Forsideillustrasjon/Front page illustration: Colourbox.com Trykk/Print: Nordberg Trykk AS Opplag/ Number printed: 1200 Bestilling/Order: [email protected] Fax: +47-21 07 81 05 Tel: +47-21 07 82 00 ISSN: 0332-6535 ISBN: 978-82-8082-252-9 trykt utgave/printed version ISBN: 978-82-8082-253-6 elektronisk utgave/electronic version 2 Rapport 2008 • Folkehelseinstituttet Forord Bruken av legemidler i befolkningen er økende. En viktig målsetting for norsk legemiddelpolitikk er rasjonell legemiddelbruk. En forutsetning for arbeidet med å optimalisere legemiddelbruken i befolkningen er kunnskap om hvilke legemidler som brukes, hvem som bruker legemidlene og hvordan de brukes. For å få bedre kunnskap på dette området, vedtok Stortinget i desember 2002 å etablere et nasjonalt reseptbasert legemiddelregister (Reseptregisteret). Oppgaven med å etablere registeret ble gitt til Folkehelseinstituttet som fra 1. januar 2004 har mottatt månedlige opplysninger fra alle apotek om utlevering av legemidler til pasienter, leger og institusjoner. Denne rapporten er første utgave i en planlagt årlig statistikk fra Reseptregisteret.
    [Show full text]
  • Hepatotoxicity Associated with Nutritional Supplements Containing Anabolic Steroids
    Case Report Annals of Clinical Case Reports Published: 26 Jan, 2018 Hepatotoxicity Associated with Nutritional Supplements Containing Anabolic Steroids Guaraná de Andrade Thais*, Vargas Karen Arce, Biccas Beatriz Nunes, Carvalho Angela Cristina Gouvêa, Agoglia Luciana and Esberard Eliane Bordalo Cathalá Department of Medicine and Pathology, Antônio Pedro University Hospital, Federal Fluminense University, Brazil Abstract Background and Objectives: The objective of this article was to emphasize the hepatotoxicity associated with the use of nutritional supplements and anabolic-androgenic steroids, as well as discussing the sale of the latter as a dietary supplement. Methods: This is a case series of two patients who developed hepatic damage after the consumption of anabolic-androgenic steroids, accompanied by a detailed bibliographic research on this topic. Results: We present two young men who developed significant liver damage, both with hyperbilirubinemia pattern after consumption of anabolic-androgenic steroids. This was associated with considerable morbidity, although both recovered without liver transplantation. The two anabolic-androgenic steroids were being marketed as dietary supplements. Conclusions: Although classified as Class V controlled substances in Brazil, anabolic-androgenic steroids are the cause of severe hepatotoxicity. Although the National Sanitary Surveillance Agency acts in the regulation of such substances, some of these products are still marketed as dietary supplements, requiring a more rigorous surveillance by health professionals. OPEN ACCESS Introduction *Correspondence: Testosterone was discovered and isolated in 1935 and since then there have been several attempts Guaraná de Andrade Thais, Division to develop synthetic derivatives (usually by 17α-alkylation) with the goal of making it orally active of Gastroenterology and Hepatology, and prolonging its biological activity [1,2].
    [Show full text]
  • A28 Anabolic Steroids
    Anabolic SteroidsSteroids A guide for users & professionals his booklet is designed to provide information about the use of anabolic steroids and some of the other drugs Tthat are used in conjunction with them. We have tried to keep the booklet free from technical jargon but on occasions it has proven necessary to include some medical, chemical or biological terminology. I hope that this will not prevent the information being accessible to all readers. The first section explaining how steroids work is the most complex, but it gets easier to understand after that (promise). The booklet is not intended to encourage anyone to use these drugs but provides basic information about how they work, how they are used and the possible consequences of using them. Anabolic Steroids A guide for users & professionals Contents Introduction .........................................................7 Formation of Testosterone ...............................................................8 Method of Action ..............................................................................9 How Steroids Work (illustration).......................................................10 Section 1 How Steroids are Used ....................................... 13 What Steroid? ................................................................................ 14 How Much to Use? ......................................................................... 15 Length of Courses? ........................................................................ 15 How Often to Use Steroids?
    [Show full text]
  • Testosterone OH
    Health risks associated with abuse of androgenic anabolic steroids W. de Ronde, MD, PhD Dept of Internal Medicine Kennemer Gasthuis, Haarlem The Netherlands • Introduction to AAS • Possible side effects associated with abuse • Results of the Dutch AAS clinic Androgenic Anabolic Steroïds •Optimal bioavailability after oral or intramuscular administration •“isolate” anabolic (=muscle building) and androgenic (=virilizing) effects testosterone OH O OH testosterone dihydrotestosterone 5α reductase OH O aromatase O OH H OH oestradiol •Removal of methyl group (nandrolone) •Attachment methyl group •Induction of double bond (trenbolone) (methenolone) O-R •Induction of double bond (boldenone) •Attachment pyrazole ring O (stanozolole) •Attachment chlorine group (turinabole) epidemiology • 8% of regular visitors of fitnesscenters in the Netherlands • 1% AAS - 20.000 – 30.000 users in the Netherlands Dutch anti- Doping Authority 2009 Dutch legislation • manufacturing and distribution of AAS without a liscence is prohibited •Only testosterone and nandrolone are registered for medical use when prescribed by a doctor. The market •source: “friends and acquaintances” •Internet •manufacturing: eastern and southern Europe,, Middle East, Asia Quality No active substance Other active substance, higher concentration declared substance and concentration Other active substance, lower concentration Declared substance, higher concentration Declared substance, lower concentration Dutch anti-Doping Authority 2005 How it is used •cycling •stacking •post-cycle treatment
    [Show full text]
  • Effects of Androgenic-Anabolic Steroids on Apolipoproteins and Lipoprotein (A) F Hartgens, G Rietjens, H a Keizer, H Kuipers, B H R Wolffenbuttel
    253 ORIGINAL ARTICLE Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a) F Hartgens, G Rietjens, H A Keizer, H Kuipers, B H R Wolffenbuttel ............................................................................................................................... Br J Sports Med 2004;38:253–259. doi: 10.1136/bjsm.2003.000199 Objectives: To investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes. Methods: In a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2- C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined. Results: In study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l.
    [Show full text]
  • Network-Based Characterization of Drug-Protein Interaction Signatures
    Tabei et al. BMC Systems Biology 2019, 13(Suppl 2):39 https://doi.org/10.1186/s12918-019-0691-1 RESEARCH Open Access Network-based characterization of drug-protein interaction signatures with a space-efficient approach Yasuo Tabei1*, Masaaki Kotera2, Ryusuke Sawada3 and Yoshihiro Yamanishi3,4 From The 17th Asia Pacific Bioinformatics Conference (APBC 2019) Wuhan, China. 14–16 January 2019 Abstract Background: Characterization of drug-protein interaction networks with biological features has recently become challenging in recent pharmaceutical science toward a better understanding of polypharmacology. Results: We present a novel method for systematic analyses of the underlying features characteristic of drug-protein interaction networks, which we call “drug-protein interaction signatures” from the integration of large-scale heterogeneous data of drugs and proteins. We develop a new efficient algorithm for extracting informative drug- protein interaction signatures from the integration of large-scale heterogeneous data of drugs and proteins, which is made possible by space-efficient representations for fingerprints of drug-protein pairs and sparsity-induced classifiers. Conclusions: Our method infers a set of drug-protein interaction signatures consisting of the associations between drug chemical substructures, adverse drug reactions, protein domains, biological pathways, and pathway modules. We argue the these signatures are biologically meaningful and useful for predicting unknown drug-protein interactions and are expected to contribute to rational drug design. Keywords: Drug-protein interaction prediction, Drug discovery, Large-scale prediction Background similar drugs are expected to interact with similar pro- Target proteins of drug molecules are classified into a pri- teins, with which the similarity of drugs and proteins are mary target and off-targets.
    [Show full text]
  • Screening Program 2014 Organic Phosphites, Selected PBT Substances and Non- Target Screening
    ENVIRONMENTAL MONITORING M-446 | 2015 Screening program 2014 Organic phosphites, selected PBT substances and non- target screening Screening 2014 | M-446|2015 Screening 2014 | M-446|2015 COLOPHON Executive institution ISBN-no Norsk institutt for vannforskning (NIVA) and 978-82-577-6663-4 NILU - Norsk institutt for luftforskning Project manager for the contractor Contact person in the Norwegian Environment Agency Kevin Thomas & Martin Schlabach Eivind Farmen M-no NIVA-no NILU-no Year Pages Contract number 446 6928-2015 OR33/2015 2015 148 14078113 Publisher The project is funded by Norwegian Environment Agency Norwegian Environment Agency Author(s) Kevin Thomas (NIVA), Martin Schlabach (NILU), Kathrine Langford (NIVA), Malcolm Reid (NIVA) Eirik Fjeld (NIVA), Sigurd Øxnevad (NIVA), Thomas Rundberget (NIVA), Kine Bæk (NIVA), Pawel Rostkowski (NILU), Laura Röhler (NILU/NMBU) and Anders Borgen (NILU) Title – Norwegian and English Screening programme 2014: Phosphites, selected PBT substances and non-target screening Screening program 2014: Fosfitter, utvalgte PBT stoffer og hypotesefri miljøscreening Summary – sammendrag The occurrence and environmental risk of a number of phosphites and selected PBT substances are reported for wastewater effluents and leachates, as well as sediments and biota from Oslofjord and Lake Mjøsa. In addition a suspect and non-target screening approach was applied to approximatley half of the biota samples. Forekomsten og miljørisiko av en rekke nye fosfitter og utvalgte PBT stoffer er rapportert for utslipp fra avløpsrenseanlegg
    [Show full text]